Journal article
Ocular toxicities associated with antibody drug conjugates
Current opinion in ophthalmology, v 35(6), pp 494-498
01 Nov 2024
PMID: 38814581
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
To review the structure, mechanism of action, and pathophysiology of antibody-drug conjugates (ADCs) used to treat gynecological malignancies associated with ocular adverse effects.
Recent research shows tisotumab vedotin causes ocular toxicity localized to the conjunctiva, with common adverse effects being conjunctivitis, dry eye, blepharitis, and keratitis. Toxicity is likely due to targeting tissue factor (TF) in the conjunctiva, leading to direct delivery of the cytotoxic payload resulting in apoptosis and bystander killing. Mirvetuximab soravtansine causes blurred vision, keratitis, or dry eye with toxicity often localized in the cornea. Off-target inflammation appears to cause ocular adverse effects, with nonreceptor mediated macropinocytosis by corneal stem cells.
Collaboration between oncologists and ophthalmologists with adherence to mitigation protocols can decrease the risk of ocular adverse events.
Metrics
1 Record Views
Details
- Title
- Ocular toxicities associated with antibody drug conjugates
- Creators
- Rayna F Marshall - Drexel UniversityHannah Xu - University of California San DiegoMeghan Berkenstock - Johns Hopkins University
- Publication Details
- Current opinion in ophthalmology, v 35(6), pp 494-498
- Publisher
- Ovid
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- College of Medicine
- Web of Science ID
- WOS:001322587400013
- Scopus ID
- 2-s2.0-85205084766
- Other Identifier
- 991022202121904721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
Source: SDGs in the Output
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Ophthalmology